ReviewFrontiers in immunology2022
Cancer organoid co-culture model system: Novel approach to guide precision medicine.
Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 1 synthesis or guideline pooled it, 94 citations in OpenAlex.
- Recent Developments and Applicability of In Vitro Gut Microbiota Models in Biomedical Research and Digestive Diseases-A Systematic Review.Medicina (Kaunas, Lithuania) · 2026Pooled it
- Bioengineering advances in pancreatic cancer organoids for reproducible tumor microenvironment modeling.iScience · 2026Review
- Shengxian decoction suppresses malignant progression of lung adenocarcinoma by enhancing CD8Chinese medicine · 2026Article
- Gastric Cancer Organoids: Mechanistic Insights, Drug Discovery, and Translational Advances in Precision Medicine.Journal of gastric cancer · 2026Review
- Organoids: From Bench to Bedside Applications.MedComm · 2026Review
- Progress and challenges in the development of advanced pancreatic cancer organoids.Journal of experimental & clinical cancer research : CR · 2026Review
- Harnessing Cancer Stem Cells and 3D Organoids in Unravelling Spatial and Cellular Heterogeneity in Cancer.International journal of molecular sciences · 2026Review
- Harnessing Tumor Organoids to Revolutionize Immunotherapy Research.Cancer medicine · 2026Review
- Organoids: technology refining, current applications and future directions.Molecular biomedicine · 2026Review
- Ancestrally Diverse Autologous Patient-Derived Organoid-Immune Cell Coculture Platform for Addressing Immunotherapeutic Outcome Disparities in High-Grade Endometrial Cancer.Cancer research communications · 2026Article
- Recapitulating lung cancer metastasisOncology reports · 2026Review
- Methods and applications of patient-derived organoid models for immune microenvironment and immunotherapy research in multiple cancer types.Experimental hematology & oncology · 2026Review
- Immune Cell Modulation of Patient-Matched Organoid Drug Response in Precision Cancer Medicine Platform.Cells · 2026Article
- Optimized patient-derived lung cancer organoids recapitulating the immune landscape for precision therapy evaluation.Cellular oncology (Dordrecht, Netherlands) · 2026Article
- Inflammasomes meet organoids and artificial intelligence: unraveling the complexity of gynecological inflammation.Frontiers in immunology · 2026Review
- Tumor organoid-immune cell co-culture systems for precision oncology.Frontiers in cell and developmental biology · 2026Review
- Novel Mixed Cancer-Cell Models Designed to Capture Inter-Patient Tumor Heterogeneity for Accurate Evaluation of Drug Combinations.International journal of molecular sciences · 2025Article
- IL-17a induces age-related olfactory dysfunction by impairing regeneration and promoting respiratory metaplasia in mice.Nature communications · 2025Article
- Immune and Immune-Integrated Organoids as NextGeneration Platforms for Disease Modeling.MedComm · 2025Review
- Tumor organoids in cancer medicine: from model systems to natural compound screening.Pharmaceutical biology · 2025Review
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Three-dimensional cancer organoids derived from self-organizing cancer stems are ex vivo miniatures of tumors that faithfully recapitulate their structure, distinctive cancer features, and genetic signatures. As novel tools, current cancer organoids have been well established and rapidly applied in drug testing, genome editing, and transplantation, with the ultimate aim of entering clinical practice for guiding personalized therapy. However, given that the lack of a tumor microenvironment, including immune cells and fibrous cells, is a major limitation of this emerging methodology, co-culture models inspire high hope for further application of this technology in cancer research. Co-culture of cancer organoids and immune cells or fibroblasts is available to investigate the tumor microenvironment, molecular interactions, and chimeric antigen receptor-engineered lymphocytes in cancer treatment. In light of the recent progress in cancer organoid co-culture models, it is only possible to recognize the advantages and drawbacks of this novel model to exploit its full potential. In this review, we summarize the recent advances in the application of cancer organoids and co-culture models and how they could be improved in the future to benefit cancer research, especially precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.